Because of the important role of S100A7 in amplifying inflammatory process in psoriatic lesions, S100A7 becomes a potential diagnostic and therapeutic target for psoriasis
Four molecule families have peer-reviewed clinical evidence supporting their use in microinfusion-style delivery: copper tripeptide GHK-Cu (collagen synthesis, gene-expression modulation), recombinant epidermal growth factor or sh-Oligopeptide-1 (keratinocyte proliferation, dermal restructuring), polydeoxyribonucleotide PDRN (adenosine A2A receptor activation, fibroblast stimulation, anti-melanogenesis), and a multi-molecular-weight hyaluronic acid system (50 kDa to 2000 kDa fractions, each with different penetration depth and biological role)
Effect persistence monitoring: because effects outlast serum presence, endpoint timing should reflect biological process kinetics (days-weeks) rather than serum PK kinetics (hours)
BPC-157 has been documented to upregulate VEGF receptor 2 expression and to promote endothelial cell migration in capillary tube-formation assays
The peptide's immune-enhancing properties could theoretically interfere with immunosuppressive regimens
